Get to Know Dr. Suma Reddy
Medical oncologist Dr. Suma Reddy is director of the chemotherapy infusion department at St. Tammany Cancer Center, which is part of the lauded Ochsner Medical Center in New Orleans.
Reddy plays a major role in the multidisciplinary program at Ochsner that has been so successful in treating various malignancies, including both peritoneal and pleural mesothelioma.
She has expertise in gastrointestinal and thoracic oncology.
As part of a collaborative approach to treatment, Reddy works closely with highly skilled surgeons, radiation oncologists, pathologists, nurses and patient navigators to ensure the best possible care for each patient.
“I want every patient feeling like they are in good hands, getting everything they need when they come here,” Reddy said. “I think we can do that at Ochsner. It’s why I stayed, because everything was here.”
Reddy, who has been lauded for her caring doctor/patient relationships, first joined the Ochsner Health System in 2003 for her residency and then fellowship. She never left, knowing there was no better place to be for patients and doctors.
She also is part of a robust research commitment that includes the largest clinical trial network in the state, letting patients stay closer to home to participate in the latest treatment advances. With her wide range of expertise, Reddy is part of clinical trials involving thoracic and abdominal diseases.
Specialties of Dr. Suma Reddy
Dr. Suma Reddy’s Experience and Medical Education
- Ochsner Medical Center
- Ochsner Health System (Fellowship and residency)
- Kasturba Medical College, Manipal, India (M.D.)
Awards and Certifications
- American Board of Internal Medicine
- Louisiana State Medical License
- CMS Meaningful Use Stage 1 Certification
Publications of Dr. Suma Reddy
- Shankaran, V. et al. (2022, January 4). S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients. Journal of the National Cancer Institute.
- Matrana, M. et al. (2020, May 20). Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts. Journal of Clinical Oncology.
- Ramirez, R.A. et al. (2020, February). A phase II trial of pembrolizumab in combination with cisplatin or carboplatin and etoposide in chemotherapy naïve patients with metastatic or unresectable high-grade gastroenteropanncreatic or lung neuroendocrine carcinoma. Journal of Clinical Oncology.
- Kucharczyk, J. et al. (2017, December). Outcomes of Patients with Late-Relapse Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Single Institution Experience. Ochsner Journal.